North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
IL13 Signaling in Allergic Asthma
NCT05478824
Recruiting
This study will investigate the role of dupilumab in the treatment of asthma with comorbid obesity. It is hypothesized that in airway epithelial cells, unique transcriptomic and proteomic expression patterns distinguish allergic and non-allergic patients with asthma and obesity and drive significant differential responses to dupilumab. It is further hypothesized that dupilumab will increase interleukin-13 receptor alpha 2 (IL-13Rα2) levels and/or signaling activity on airway epithelial cells iso... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/12/2024
Locations: Duke Asthma Allergy and Airway Center, Durham, North Carolina
Conditions: Asthma, Allergic, Asthma, Obesity
Register for Updates
High Dose Inspiratory Muscle Training in LOPD
NCT05431127
Recruiting
Study Objectives: 1) assess the safety and feasibility of high-dose inspiratory muscle training (IMT) delivered remotely in Late-onset Pompe Disease (LOPD) and 2) determine its effects on respiratory and patient-reported outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Late-Onset Pompe Disease, Lysosomal Disease
Register for Updates
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/11/2024
Locations: MBX Biosciences Investigational Site, Greenville, North Carolina
Conditions: Hypoparathyroidism
Register for Updates
Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
NCT05883449
Recruiting
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: UNC Immunotherapy Team, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Register for Updates
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385
Recruiting
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Register for Updates
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051
Recruiting
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: GSK Investigational Site, Charlotte, North Carolina
Conditions: Neoplasms
Register for Updates
Ventripoint Single Ventricle Study
NCT05262907
Recruiting
This study will validate a coordinate-based 3-dimensional echocardiographic technique for the assessment of cardiac size and function in children and young adults with functional single ventricles.
Gender:
ALL
Ages:
All
Trial Updated:
11/08/2024
Locations: Duke University, Durham, North Carolina
Conditions: Congenital Heart Disease, Single-ventricle
Register for Updates
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
Recruiting
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Novant Health Inc, Charlotte, North Carolina
Conditions: Myelodysplastic Syndromes
Register for Updates
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT04858256
Recruiting
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: T-Cell Neoplasm, Lymphoproliferative Disorders
Register for Updates
Healthy Heart Habits-2
NCT06440278
Recruiting
Sixty adults who have experienced acute coronary syndrome within the past 2-12 months from three states (Rhode Island, North Carolina, Minnesota) will be randomized to either (1) a coaching program for depressed mood and health behavior change (Behavioral Activation for Health and Depression; BA-HD), or (2) Enhanced Usual Care. This study will evaluate the feasibility and acceptability of study procedures and BA-HD, and establish protocol and measurement harmonization across three sites in prepa... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/05/2024
Locations: ECU Health, Greenville, North Carolina
Conditions: Acute Coronary Syndrome
Register for Updates
The ACES Study for Aseptic Pleural Effusion
NCT06210685
Recruiting
The study will enroll recurrent aseptic pleural effusion patients who are designated by their physician as needing treatment to control the fluid. Baseline assessment will include a history and physical, chest imaging and quality of life questionnaires. After ACES implantation, patients will remain under hospital care for general observation as per standard-of-care before being discharged home with access to electronic diaries for tracking pain and dyspnea.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/05/2024
Locations: University of North Carolina Pulmonary and Critical Care Medicine, Chapel Hill, North Carolina
Conditions: Pleural Effusion
Register for Updates
Cardiovascular Effects of Very Low Nicotine Content Cigarettes
NCT05707871
Recruiting
The study is measuring Cardiovascular effects of very low nicotine content cigarettes on daily and non-daily smokers
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/05/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Tobacco Use
Register for Updates